Neurotoxicity in a phase I trial of cont
โ
Gerald H. Clamon; Lynn Baatz; Henry T. Hoffman; David H. Hussey; Matthew Glascoc
๐
Article
๐
1996
๐
John Wiley and Sons
๐
English
โ 569 KB
## Background: Both twice daily fractionated radiotherapy and concurrent cisplatin with once-daily radiotherapy have been shown to improve local disease control in patients with head and neck cancer. the objective of this phase i trial was to determine the maximum tolerated dose of cisplatin which